We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urine-Based Genomic Test Identifies Hematuria Patients at High Risk for Bladder Cancer

By LabMedica International staff writers
Posted on 11 Oct 2023

Blood in the urine, or hematuria, is the primary symptom that leads to a bladder cancer diagnosis. More...

However, only between 5% and 20% of patients with hematuria are diagnosed with bladder cancer after undergoing a cystoscopy, which makes it crucial to determine the exact cause of the symptom. Now, a noninvasive, urine-based test that helps accurately triage hematuria patients has been shown to significantly improve the detection of those at a higher risk for bladder cancer.

Vesica Health’s (Irvine, CA, USA) AssureDx is a noninvasive urine test that assesses genomic changes related to bladder cancer, assisting in the identification of patients who would benefit from a clinical assessment by an urologist. Additionally, it helps identify patients at low risk, allowing them to avoid invasive and potentially harmful diagnostic procedures. AssureDx is also valuable for urologists as it provides a noninvasive way to monitor patients with a higher risk of cancer recurrence post-treatment, thus aiding in better patient management and outcomes.

The latest study focused on a group of 838 subjects who had experienced hematuria and were previously tested using AssureDx. The subjects were sorted into risk categories defined by the American Urological Association (AUA) based on factors like age, sex, and type of hematuria, which is also known as urothelial carcinoma (UC). The multi-omics biomarker analysis conducted by AssureDx examined DNA mutations in genes FGFR3, TERT, and HRAS as well as DNA methylation statuses for genes OTX1, ONECUT2, and TWIST1. When applied, AssureDx exhibited strong performance across all risk categories, scoring a 0.96 AUC (area under the receiver operating characteristic curve) for the complete cohort. This study substantiates the effectiveness of AssureDx in enhancing the AUA's guidelines for diagnosing hematuria. The study was published in the European Urology Oncology journal.

"Publication of this pivotal study in a leading international urology journal, demonstrating AssureDx enhances the AUA Guidelines, underscores the importance of the test for risk stratification of hematuria patients and identification of those at increased risk for bladder cancer," said Christopher Thibodeau, Chief Executive Officer of Vesica Health. "Results from this study provide further clinical evidence that the AssureDx test delivers actionable information to improve the early detection of bladder cancer when there is the greatest opportunity for cure."

Related Links:
Vesica Health 


New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.